KEYNOTE SPEAKER: CGMP Requirements for Early Clinical Development: Implication of FDA Guidance Document. Brenda P. Fielding, Regulus Pharmaceutical Consulting, LLC

Opening Remarks

Selection and Performance of Internal Reference Standards for LC/MS/MS in Clinical and Pre-Clinical Pharmacokinetic Studies of Oncology Drug Development. Daniel L. Gustafson and Joseph A. Zirrolli, University of Colorado Health Sciences Center

Affinity Selection Mass Spectrometry (ASMS) in Oncology Drug Discovery to Identify Small Molecule Inhibitors of Novel Target Proteins. Andrew Cooke, OSI Pharmaceuticals

Lunch (complimentary buffet included with registration fee)

Opening Remarks

Liquid Chromatography Electrospray Ionization Mass Spectrometry Analysis of the Ocular Metabolites from a Short Interfering RNA Duplex. Mike Beverly, Sirna Therapeutics, Inc.

An Online Desalting LCMS Method for In-process Analysis of Commercial Scale, Therapeutic Oligonucleotides. J. Shawn Roach and Douglas Brooks, OSI(eyetech) Inc.

Break (refreshments in exhibition area)

The Analytical Challenge of a Complex, Dynamic Proteome; Methods for Confident Protein Characterization and Quantification. Dr. Iggy Kass, Waters Corporation

Applications of Machine Learning to LC-MS/MS for Improved Proteomic Analyses. Dr. David Anderson, University of Oregon

Closing Remarks